Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Next Gen TROP2 ADC
- Development stage
- Preclinical
- Lead developer
- Oqory
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Next Gen TROP2 ADC is a preclinical-stage antibody-drug conjugate (ADC) being developed by Vivasor (formerly Oqory). It is designed to target Trophoblast cell-surface antigen 2 (TROP2), a glycoprotein frequently overexpressed in various epithelial cancers, including breast and lung carcinomas. This next-generation candidate is engineered for reduced immunogenicity and utilizes a novel payload-linker system, specifically employing either Camptothecin (C-lock) or Camptothecin/DXD (C-lock/DXD) as the cytotoxic payload. The drug is currently under investigation for the treatment of HER2-positive and HER2-negative breast cancers, as well as other advanced or metastatic solid tumors.
- Other names
- Vivasor TROP2 ADC
02
Targets
TOP1 (DNA Topoisomerase I)TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on Next Gen TROP2 ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Next Gen TROP2 ADC.